ANL · NASDAQ · Biotechnology

Adlai Nortye (ADR) (ANL)

Develops clinical-stage cancer therapies targeting RAS pathways and immune responses.

$16.40
vs last close−0.20 (−1.20%)

Something off on this page? Send us feedback.

EPSReportedEstimate

Apr '24Aug '24Feb '25Apr '25Aug '25Dec '25Apr '26Aug '26
Reported−$1.59−$0.35−$0.22−$0.22−$0.18−$0.18−$0.81−$0.04
Estimate−$0.38−$1.06−$0.53−$0.53−$0.18−$0.18−$0.18−$0.04
Surprise−318.4%+67.0%+58.5%+58.5%0.0%0.0%−350.0%+7.9%

RevenueReportedEstimate

Apr '24Aug '24Feb '25Apr '25Aug '25Dec '25Apr '26Aug '26
Reported$745.0K$745.0K$2.5M$14.7M
Estimate$745.0K$313.2K$450.3K$12.5M
Surprise0.0%+455.2%+17.5%

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.12
Sep 2027−$0.11
Jun 2027−$0.15
Mar 2027−$0.04
Dec 2026−$0.11
Mar 2027−$0.15
Aug 2026−$0.04−$0.04+7.9%
Apr 2026−$0.18
Apr 2026−$0.18−$0.81−350.0%
Dec 2025−$0.18−$0.180.0%
Aug 2025−$0.18−$0.180.0%
Apr 2025
Feb 2025
Aug 2024
Apr 2024
Feb 2024
Nov 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Jan 1970−$0.38

The latest year is open to everyone — the 14 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.12$4.8M
Sep 2027−$0.11$5.1M
Jun 2027−$0.15$3.5M
Mar 2027−$0.04$12.5M
Dec 2026−$0.11$4.0M
Mar 3, 2027−$0.15$3.5M
Aug 14, 2026−$0.04−$0.04+7.9%$12.5M$14.7M+17.5%+0.7%
Apr 29, 2026−$0.18$2.3M
Apr 10, 2026−$0.18−$0.81−350.0%$450.3K$2.5M+455.2%+8.1%
Dec 29, 2025−$0.18−$0.180.0%$313.2K−17.2%
Aug 7, 2025−$0.18−$0.180.0%0.0%
Apr 30, 2025
Feb 26, 2025
Aug 8, 2024
Apr 20, 2024
Feb 28, 2024
Nov 29, 2023
Sep 12, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Jan 1, 1970−$0.38

The latest year is open to everyone — the 14 quarters behind it read with an account.